Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)Daniel L. Hertz, Maryam B. Lustberg, Lisa Grech et al.|Cancer Treatment Reviews|2021Cited by 63
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapyYael Kusne, Mrinal M. Patnaik, Oliver Sartor et al.|Haematologica|2025Cited by 3
Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with <sup>177</sup>Lutetium.Yael Kusne, Mrinal M. Patnaik, Stephanie Pritzl et al.|Journal of Clinical Oncology|2024Cited by 2
Clonal Hematopoiesis Landscape in Metastatic Prostate Cancer PatientsYael Kusne, Mrinal M. Patnaik, Osama Mosalem et al.|Blood|2024Cited by 1
Inherited DNA repair variants are associated with clonal hematopoiesis and cardiovascular risk in men with metastatic prostate cancerOlisaemeka Ogbue, Mrinal M. Patnaik, Yael Kusne et al.|Haematologica|2025Cited by 0